CAI vs PSNL
CAI: Caris Life Sciences delivers precision oncology and molecular profiling solutions that help biopharma companies and physicians make treatment decisions through comprehensive tumor analysis. PSNL: A genomic testing company enabling precision oncology through ultra-sensitive liquid biopsy and tumor sequencing to detect cancer recurrence and guide personalized treatment decisions.
Side-by-side fundamentals
| Metric | CAI | PSNL | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $16.09 | $12.28 | |
| Market cap as of 2026-07-31 | $4.4B | $1.3B | |
| P/E as of 2026-07-31 | 141.51 | n/a | |
| PEG as of 2026-07-31 | -0.97 | n/a | |
| Net margin as of 2026-07-31 | +3.8% | -148.1% | CAI higher |
| Gross margin as of 2026-07-31 | +68.7% | +13.7% | CAI higher |
| Operating margin as of 2026-07-31 | +9.8% | -158.9% | CAI higher |
| ROE as of 2026-07-31 | +6.5% | -43.5% | CAI higher |
| ROA as of 2026-07-31 | +3.2% | -32.9% | CAI higher |
| Debt / equity as of 2026-07-31 | 0.64 | 0.00 | PSNL lower |
| Revenue growth (YoY) as of 2026-07-31 | +78.8% | -24.7% | CAI higher |
| Revenue CAGR (3y) SEC XBRL | +62.9% | +2.3% | CAI higher |
| Beta as of 2026-07-31 | 1.33 | 2.18 | |
| 1-year return as of 2026-07-30 close | -45.5% | +119.7% | PSNL higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.